In conclusion, our study suggests that the combination of sotorasib and the next-generation WEE1 inhibitor ZN-c3 is a promising treatment for KRAS-G12C-mutated lung cancer with TP53 mutations. The gene discussed is WEE1; the disease is lung carcinoma.